Bone pain and extremely low bone mineral density due to severe vitamin D deficiency in celiac disease

Abstract

Case report

A 29-year-old wheelchair-bound woman was presented to us by the gastroenterologist with suspected osteomalacia. She had lived in the Netherlands all her life and was born of Moroccan parents. Her medical history revealed iron deficiency, growth retardation, and celiac disease, for which she was put on a gluten-free diet. She had progressive bone pain since 2 years, difficulty with walking, and about 15 kg weight loss. She had a short stature, scoliosis, and pronounced kyphosis of the spine and poor condition of her teeth. Laboratory results showed hypocalcemia, an immeasurable serum 25-hydroxyvitamin D level, and elevated parathyroid hormone and alkaline phosphatase levels. Spinal radiographs showed unsharp, low contrast vertebrae. Bone mineral density measurement at the lumbar spine and hip showed a T-score of −6.0 and −6.5, respectively. A bone scintigraphy showed multiple hotspots in ribs, sternum, mandible, and long bones. A duodenal biopsy revealed villous atrophy (Marsh 3C) and positive antibodies against endomysium, transglutaminase, and gliadin, compatible with active celiac disease. A bone biopsy showed severe osteomalacia but normal bone volume. She was treated with calcium intravenously and later orally. Furthermore, she was treated with high oral doses of vitamin D and a gluten-free diet. After a few weeks of treatment, her bone pain decreased, and her muscle strength improved.

Discussion

In this article, the pathophysiology and occurrence of osteomalacia as a complication of celiac disease are discussed. Low bone mineral density can point to osteomalacia as well as osteoporosis.

Introduction

Low bone mineral density is the first diagnostic criterion in patients with osteoporosis. Osteomalacia is however also characterized by a low BMD. In this article, we will present a patient referred to our hospital with an extremely low bone mineral density due to severe osteomalacia with longstanding celiac disease. It is important to distinguish between osteoporosis and osteomalacia because they differ with regard to therapy and prognosis.

Case history

A 29-year-old woman of Moroccan origin was admitted to the Department of Gastroenterology because of refractory celiac disease and suspected osteomalacia. Her medical history revealed growth retardation and iron deficiency from the age of 6 and the diagnosis of celiac disease at the age of 17. At the age of 27, there was an ongoing symptomatic celiac disease despite a gluten-free diet. On admittance to our hospital, the patient complained of progressive bone pain over the last 2 years, mainly located in the ribs, spine, hips, and shoulders. She also had severe difficulty with walking and was in fact wheelchair-bound. She was short of breath during normal daily activities and had lost 15 kg in 3 years. She had a regular menstrual cycle, and her menarche was at 17 years of age. She had neither abdominal complaints nor diarrhea. On physical examination, she was pale. Her body height was 148 cm (previously 156 cm) and her weight, 38 kg. She had bad dentition, and the back showed a scoliosis and pronounced thoracic kyphosis with thoracic and lumbar percussion pain. Pelvis and shoulders also were painful on touching. There was muscle atrophy and symmetrical loss of proximal muscle strength.

Laboratory evaluation at presentation showed hypocalcemia, low serum phosphate, high alkaline phosphatase, and a serum 25-hydroxyvitamin D (25(OH)D) level below the detection limit, as shown in Table 1. The serum parathyroid hormone level was strongly elevated. Furthermore, the patient had low serum vitamin A (0.9 μmol/L; normal, 1.2–3.0), vitamin B1 (78 nmol/L; normal, 80–160), and vitamin B6 (6 nmol/L; normal, 13–80) levels. Her serum folic acid level (30.7 nmol/L; normal, >6) and serum vitamin B12 level were normal (150 pmol/L; normal, 10–700), and there were no signs of iron deficiency. At that moment, she was using the following medications prescribed in the referring hospital: calcium carbonate 1,000 mg twice daily, naproxen 500 mg twice daily, pantoprazole 20 mg once daily, tramadol 50 mg twice daily, ferrioxidesaccharaat 200 mg once a week (intravenous), alfacalcidol 0.5 μg once daily (intravenous), alendronic acid 70 mg once a week, and folic acid 5 mg once daily (intravenous).

Table 1.

Results of laboratory evaluation, BMD measurement and histomorphometry

Laboratory evaluation	Patient	Reference values
Calcium	1.94 mmol/L	2.20–2.60 mmol/L
Phosphate	0.71 mmol/L	0.70–1.40 mmol/L
Albumin	35 g/L	35–52 g/L
Alkaline phosphatase	386 U/L	<120 U/L
25 hydroxy vitamin D	<10 nmol/L	25–150 nmol/L
1,25 hydroxy vitamin Da	76 pmol/L	50–160 pmol/L
Parathyroid hormone (fasting)	75 pmol/L	<11 pmol/L
DXA	BMD	T-score, Z-score
LWK (L1–L4)	0.390 g/cm²	−6.0, −6.0
Hip	0.153 g/cm²	−6.5, −6.4
Bone histomorphometry
Trabecular bone volume (%)	BV/TV = 37.48%
Osteoid (%)	OV/BV = 75.07%
Trabecular thickness	261 μm
Osteoid thickness	98.5 μm

^aAfter initiating vitamin D therapy

Radiographs of the thoracic and lumbar spines had a milk glass appearance and were not sharply delineated. The lumbar vertebrae had a biconcave codfish appearance (Fig. 1a, b) Bone mineral density measurement (Hologic) showed extremely low absolute values and T-scores (Table 1). A skeletal scintigraphy with technetium-99 M showed a diffusely elevated uptake in sternum, mandible, and long bones and an absent kidney sign. There were also multiple symmetric focal lesions with enhanced uptake in the ribs, compatible with rib fractures or fissures (Fig. 2a, b). To confirm the clinical diagnosis of osteomalacia in this patient with severe refractory celiac disease and extremely low BMD, a bone biopsy was obtained from the right iliac crest (Fig. 3a–c). This biopsy showed a relative osteoid volume of more than 70% and signs of increased bone turnover compatible with secondary hyperparathyroidism. The osteoid was covered with high numbers of active osteoblasts, and resorption lacunae were filled with multinucleated osteoclasts. Peri-trabecular fibrosis was also observed. The trabecular bone volume (BV/TV) was normal, i.e., not compatible with osteoporosis.

Fig. 1.

Radiographs, lateral view, of the lower thoracic (a) and lumbar vertebrae (b). Thoracic vertebrae are blurred and lumbar vertebrae show codfish appearance

Fig. 2.

Bone scintigraphy; Whole body, anterior view (a) and detail of the ribs, lateral view (b). Hot spots may indicate pseudofractures or fissures

Fig. 3.

Crista biopsy; Goldner stain, magnification 5 × 10 (a), Goldner stain, magnification 10 × 10 (b), and Tartrate-resistant acidic phosphatase stain, magnification 10 × 10 (c). Mineralized bone is green and osteoid tissue, red. Osteoid seems very thick, and osteoid volume is 75%. Bone resorption by multinucleated osteoclasts is increased (arrows)

This Moroccan young woman with refractory celiac disease had a very severe osteomalacia with an extremely low bone mineral density due to a severe vitamin D deficiency. Treatment with alendronic acid was discontinued, and the patient was treated during 14 days with intravenous calcium glubionate up to 8,250 mg (540 mg or 13.5 mmol Ca⁺⁺) daily and oral cholecalciferol 10,000 IU daily. After these 14 days, her medication consisted of 7 g of calcium carbonate and 1,200 IU cholecalciferol daily in an outpatient setting. After the intravenous treatment, the serum 25(OH)D level increased to 56 nmol/L, and the symptoms of the patient rapidly improved; the bone pain decreased, muscle strength and physical performance improved markedly, and she was able to walk unassisted.

After initiating oral treatment with calcium and lowering the cholecalciferol dose, there was a gradual decline of 25(OH)D, and we had to increase the oral dose of cholecalciferol to 10,000 IU a day. Questioning revealed gluten exposure and patient was given advice repeatedly on how to maintain a strict gluten-free diet. After raising the oral dose of cholecalciferol, the serum 25(OH)D level increased to 34 nmol/L, and the 1,25(OH)vitamin D to >250 pmol/L. Bone mineral density measurement 5 1/2 months after initiation of therapy showed a significant increase at the lumbar spine (L1–L4) and hip, 0.44 g/cm² (T-score, −5.5) and 0.22 g/cm² (T-score, −5.9), respectively. Further follow-up of this patient was not possible because she did not respond to multiple invitations to visit our outpatient clinic.

Discussion

Osteomalacia is seldom described as a complication of celiac disease and rarely seen as presenting clinical condition [2, 5, 10]. In our patient, osteomalacia was a late complication of ongoing celiac disease due to poor compliance regarding gluten-free diet. Osteomalacia may occur as a consequence of severe longstanding vitamin D deficiency when sunshine exposure is very low [10, 24]. Sunshine exposure still is the main source of vitamin D. It is highly likely that in our patient, a pigmented skin, covered by clothes, and the northern latitude of the Netherlands have contributed to the severity of the osteomalacia. Also, calcium malabsorption causes secondary hyperparathyroidism, and the latter results in an enhanced metabolic breakdown of vitamin D metabolites [3, 4, 14, 19, 22]. Calcium malabsorption in celiac disease is due to villous atrophy in the proximal intestine. Villous atrophy causes a reduction of active absorption of calcium and an increase of unbound intraluminal fatty acids that bind intraluminal calcium and inhibit absorption. Vitamin D receptor resistance in the intestinal wall has been suggested, and the amount of vitamin D-dependent calcium-binding proteins in the intestinal wall appears to be reduced in active disease [19]. Other factors could also reduce bone mineral density, such as secondary amenorrhea induced by low body weight [6, 13, 18], lactose intolerance, immobility [9], inflammation [7, 20], and antibodies against regulating proteins [17].

Common symptoms of osteomalacia are proximal muscle weakness, difficulty with walking and especially climbing stairs, a waddling gait, difficulty with rising out of a chair, and bone pain [9]. After initiating treatment for osteomalacia, the symptoms typically disappear within weeks to months [8, 10]. During clinical recovery, the alkaline phosphatase rises temporarily due to enhanced bone formation, after which it normalizes. The relatively high serum level of 1,25-dihydroxyvitamin D as compared to 25(OH)D is due to secondary hyperparathyroidism that causes an enhanced 1α-hydroxylase activity [11].

Response to therapy is illustrated very elegantly in an early case report by Gershon et al. Symptoms, biochemical markers of bone turnover, and bone structure normalized within several months after initiating vitamin D therapy, and an electromyography of different muscles improved markedly [9].

This patient illustrates all features of severe osteomalacia: a low serum calcium and phosphate, an elevated alkaline phosphatase, a very low bone mineral density, signs of bone fissures or pseudofractures on skeletal scintigraphy, and unsharp milky radiographs with codfish vertebrae. The bone biopsy showed severe osteomalacia and secondary hyperparathyroidism. The very low serum 25(OH)D and the severe consequences may also be due to the fact that she was a non-western immigrant. The latter group carries a high risk of severe vitamin D deficiency in the Netherlands as serum 25(OH)D was lower than 25 nmol/L (10 ng/ml) in about half of Turkish and Moroccan immigrants in a recent survey [23]. The unsharp delineation of the radiographs is probably due to the very thick osteoid seams, about seven times the upper limit of normal. The height loss of the patient may be due to vertebral height loss. It might partly be reversible since this is also seen in patients with juvenile osteoporosis.

Our patient had severe mobility problems and muscle weakness. In order to initiate a quick improvement, she was treated with calcium infusions since oral calcium would not be absorbed adequately before healing of the gluten-sensitive enteropathy. Bone mineralization does not depend on vitamin D as long as sufficient calcium and phosphate are available [25]. The therapeutic use of calcium infusions has been described earlier [1].

Several studies examined bone mineral density in adults with celiac disease consuming a gluten-free diet. Most studies show a decrease in BMD which improves when a gluten-free diet is instituted, but loss of BMD is usually not fully reversible [4, 12, 15, 16, 21]. Most patients will experience bone loss due to secondary hyperparathyroidism following vitamin D deficiency. Another aspect is that that a very low BMD can indicate osteomalacia as well as osteoporosis.

In celiac disease, osteomalacia should be suspected when the patient complains of bone pain and muscle weakness, serum 25(OH)D is very low, and alkaline phosphatase is elevated. It is seldom the presentation of an undiagnosed celiac disease. Therapy should be initiated as soon as possible to prevent bone loss and disability.